Skip to content

Efficacy and safety of intra-articular steroid injection for inflamed atlantoaxial joint in patients with rheumatoid arthritis

In patients with rheumatoid arthritis and inflamed atlantoaxial joint, is intra-articular steroid injection,compared with systemic steroid administration effective and safe?

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12616000750482
Enrollment
60
Registered
2016-06-07
Start date
2016-06-15
Completion date
Unknown
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Rheumatoid arthritis is a chronic inflammatory disease involving multiple joints. The cervical spine is often affected, and cases involving atlantoaxial joint can lead to instability. Anterior atlantoaxial subluxation in RA patients can lead to posterior neck pain or occipital headache. intraarticular steroid injection of AAJ could stop the joint destruction

Interventions

(AS) group, received intra-articular steroid injection for atlantoaxial joint following failure of systemic steroids (prednisolone, oral tablet, 5 mg/3 times daily for 2 weeks) administration as part of the trial to resolve inflammation of the atlanto-axial joint assessed by MRI , (adherence to treatment is confirmed by empty drug packet return), in addition to intramuscular methotrexate 12.5 mg per week and hydroxychloroquine, oral tablet 200 mg, 2 tablets per day (regular treatment for patient

(AS) group, received intra-articular steroid injection for atlantoaxial joint following failure of systemic steroids (prednisolone, oral tablet, 5 mg/3 times daily for 2 weeks) administration as part of the trial to resolve inflammation of the atlanto-axial joint assessed by MRI , (adherence to treatment is confirmed by empty drug packet return), in addition to intramuscular methotrexate 12.5 mg per week and hydroxychloroquine, oral tablet 200 mg, 2 tablets per day (regular treatment for patients with rheumatoid arthritis that continues for life).Injection technique: With the patient placed in the prone position and a pillow under the chest to allow for slight neck flexion, the C-arm is brought to the head of the table in an anteroposterior direction. The C-arm is rotated in a cephalad-caudad direction to better visualize the lateral atlantoaxial joint (AAJ). The needle insertion site is marked on the skin overlying the lateral third of the AAJ. The skin is prepped and draped in the usual sterile fashion, and a skin wheel is raised with 3 ml of lidocaine 1 % at the insertion site. Then, a 22 G 3 and 1/2 inches blunt needle is advanced towards the posterolateral aspect of the inferior margin of the inferior articular process of the atlas (C1). Then, a lateral view is obtained. The needle is withdrawn slightly, directed towards the posterolateral aspect of the (AAJ), and advanced for 2 millimetres. Usually a distinctive pop is felt signalling entering the joint cavity. After careful negative aspiration for blood or cerebrospinal fluid, 0.2 ml of omnipaque dye is injected to verify intra-articular placement of the tip of the needle under direct real-time fluoroscopy to check for inadvertent intra-arterial injection. Anteroposterior and lateral views are obtained to insure that the contrast agent remained confined to the joint cavity without escape to the surrounding structures and finally, 1.0 ml of a mixture of bupivacaine 0.5 % and 20 mg of triamcinolone is injected. The injection will be performed once (will not repeated) bilaterally ( both AAJ). The injection will be done by senior staff pain clinician.

Sponsors

Diab Fuad Hetta
Lead SponsorIndividual

Study design

Allocation
Randomised controlled trial
Primary purpose
Treatment

Eligibility

Sex/Gender
All
Age
15 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

Patients with rheumatoid arthritis with MRI findings of atlantoaxial joint inflammation and failure of resolution after 2 weeks systemic steroid administration

Exclusion criteria

Coagulopathy, allergy to contrast material, pregnancy

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026